Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial

Preeta Tyagi, Chandra P. Belani

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial'. Together they form a unique fingerprint.